Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | HTT | P42858 | 4/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | BLM | P54132 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | SOS1 | Q07889 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29559166 | 0.86 | SOS1 (0.59) | MAPTSMN1; SMN2KMT2AMEN1HTT | |
| Ammonia Solution, Strong SCHEMBL4275957 | 0.83 | MAPT (0.47) | MAPTSMN1; SMN2KMT2AMEN1HTT | |
| SCHEMBL3052123 | 0.83 | SMN1; SMN2 (1.00) | MAPTSMN1; SMN2KMT2AMEN1HTT | |
| SCHEMBL3051396 | 0.81 | TP53 (0.55) | MAPTSMN1; SMN2KMT2AMEN1HTT | |
| SCHEMBL3048542 | 0.76 | MAPT (0.47) | MAPTSMN1; SMN2KMT2AMEN1HTT | |
| SCHEMBL5539670 | 0.75 | MAPT (0.45) | MAPTSMN1; SMN2KMT2AMEN1HTT | |
| SCHEMBL3050864 | 0.75 | MAPT (0.47) | MAPTSMN1; SMN2KMT2AMEN1HTT | |
| SCHEMBL6418253 | 0.75 | MAPT (0.50) | MAPTSMN1; SMN2KMT2AMEN1HTT | |
| SCHEMBL3059036 | 0.75 | TP53 (0.53) | MAPTSMN1; SMN2KMT2AMEN1HTT | |
| SCHEMBL22342966 | 0.75 | SOS1 (0.83) | MAPTSMN1; SMN2KMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178754-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-07-12 | — | — | US | claimed |
| US-20100222356-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2010-09-02 | — | — | US | claimed |
| EP-1799689-A1 | FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS | Compass Pharmaceuticals LLC (US) | 2007-06-27 | — | — | EP | claimed |
| WO-2006044402-A1 | FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2006-04-27 | — | — | WO | claimed |
| US-20120178754-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-07-12 | — | — | US | disclosed |
| US-20100222356-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2010-09-02 | — | — | US | disclosed |
| EP-1799689-A1 | FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS | Compass Pharmaceuticals LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006044402-A1 | FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222356-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | CDC73, VHL, RB1 | MAPT 3908/4885SMN1; SMN2 243/4885KMT2A 3960/4885 |
| US-20120178754-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | CDC73, VHL, RB1 | MAPT 3908/4885SMN1; SMN2 243/4885KMT2A 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.